Are you curious about pertuzumab and how it works in the medical field? Do you want to learn everything there is to know about this powerful medication, including its indications, dosing, and side effects? Look no further! In this comprehensive guide, we will break down all the information you need to understand pertuzumab. From breast cancer treatment to its unique mechanism of action, we've got you covered.
Pertuzumab (brand name Perjeta) is a prescription medication used to treat breast cancer. It’s a type of targeted therapy that works by interfering with the growth and spread of cancer cells. Pertuzumab is given as an infusion into a vein (IV). It’s usually given with other cancer medications.
Common side effects of pertuzumab include nausea, vomiting, diarrhea, constipation, headache, tiredness, low blood cell counts, and infusion-related reactions. Serious side effects can also occur. Pertuzumab can interact with other medications, herbs, or vitamins you might be taking.
Pertuzumab is a monoclonal antibody that targets the HER2 protein. The HER2 protein is found on the surface of some breast cancer cells. About 1 out of every 5 breast cancers is HER2-positive. These types of breast cancers tend to grow and spread more quickly than other types of breast cancer. Pertuzumab slows or stops the growth of HER2-positive breast cancer cells by binding to the HER2 protein and preventing it from working properly
Pertuzumab is a humanized monoclonal antibody that targets the HER2 protein. It is used in combination with other cancer treatments, such as trastuzumab and docetaxel, to treat HER2-positive breast cancer.
Pertuzumab can cause serious side effects, including heart problems, gastrointestinal problems, and infusion reactions.
Some common side effects of pertuzumab include nausea, vomiting, diarrhea, constipation, headache, fatigue, muscle pain, joint pain, and skin rash. These side effects usually go away after a few weeks of treatment.
Pertuzumab is a monoclonal antibody that works by targeting a protein called HER2, which is found on the surface of some cancer cells. By targeting this protein, pertuzumab can help to kill cancer cells or stop them from growing.
Like all medications, pertuzumab can cause side effects. The most common side effects of pertuzumab include:
• Nausea and vomiting
• Diarrhea
• Skin rash or itching
• Fatigue
• Headache
• Musculoskeletal pain
Less common side effects of pertuzumab include:
• Low blood counts (anemia, neutropenia, thrombocytopenia)
• Infusion-related reactions (fever, chills, nausea/vomiting, low blood pressure)
• Heart problems (heart failure, left ventricular ejection fraction [LVEF] decrease)
As a comprehensive guide to understanding pertuzumab, this article has discussed the drug's indications, dosing, and potential side effects. In summary, pertuzumab is indicated for use in the treatment of non-small cell lung cancer and HER2-positive breast cancer. It is given as an intravenous infusion every three weeks with or without other treatments depending on each patient’s individual case. The most common side effects associated with its use include fatigue, nausea ,and diarrhea.
1.
EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues
2.
Universal screening approach achieves a comparable detection rate of lung cancer
3.
GLP-1 drugs linked to dramatically lower death rates in colon cancer patients
4.
The response of bipolar patients to lithium may be predicted by ancestry.
5.
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study
1.
Aging of Bone-Marrow Immune Niches: Mechanisms, Clinical Impact, and Therapeutic Horizons
2.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
3.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
4.
Precision Supportive Oncology: Managing Immune Toxicity, Treatment-Related Critical Illness and Long-Term Quality of Life
5.
Environmental Carcinogen Exposure Risk Modeling: Current Evidence and Clinical Implications
1.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Symposium on Oncology, Cardiology and Critical Care Innovations
4.
International Conference on Cancer Nursing and Hematology Support
5.
International Conference on Clinical Medicine and Surgical Care
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Understanding the Role of Screening in Cancer Prevention
3.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XII
5.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation